Positive Phase III data from Gilead's elvitegravir
This article was originally published in Scrip
Executive Summary
Gilead Sciences has reported that its novel oral HIV integrase inhibitor, elvitegravir, has met the primary endpoint in an ongoing Phase III trial investigating the product for the treatment of HIV-1 infection in treatment-experienced patients. The company plans to submit regulatory applications for elvitegravir in 2012.